The Filing Desk

Coherus Oncology vs Editas Medicine

Coherus Oncology CHRS · Editas Medicine EDIT · Biotechnology

Coherus Oncology reported revenue of $42 million in fiscal 2025, about the same as Editas Medicine's $40 million in fiscal 2025. Coherus Oncology's revenue grew 59.8% in its latest year, and Editas Medicine's grew 25.4%. Coherus Oncology had an operating margin of -429.5%, against -394.9% at Editas Medicine.

Side by side

Coherus OncologyEditas Medicine
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$42M$40M
Revenue growth59.8%25.4%
Revenue growth a year, last 5 years−38.4%−14.9%
Gross margin67.2%—
Operating margin−429.5%−394.9%
Net margin398.4%−395.0%
Free cash flow—−$166M
Free cash flow margin—−409.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.3%7.8%
Last close$0.39$1.71
P/E at the last close——
Insider trades, last 12 months—sold $106,705
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Coherus OncologyEditas Medicine
Operating margin
Percent of revenue
Coherus OncologyEditas Medicine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Coherus OncologyEditas Medicine

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Coherus Oncology and Editas Medicine pages.